Josh Allen

Josh Allen

Company: Oncoceutics

Job title: Chief Scientific Officer

Seminars:

Targeting DRD2 and ClpP in High Grade Glioma with ONC201: Emerging Clinical Results and Future Trials 12:45 pm

Review DRD2 as therapeutic target in oncology Update on the latest ONC201 clinical results in H3 K27M-mutant gliomas Overview of ONC201 in other CNS tumors and emerging trialsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.